% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/data.R
\docType{data}
\name{VT}
\alias{VT}
\title{EQ-5D-5L VT value set data}
\format{
An object of class \code{data.frame} with 35 rows and 29 columns.
}
\source{
\enumerate{
    \item{\strong{Belgium}: Bouckaert N, Gerkens S, Devriese S, Cleemput I. An EQ-5D-5L value set for Belgium – How to value health- related quality of life? Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE). 2021. KCE Reports 342. D/2021/10.273/19. \href{https://www.kce.fgov.be/sites/default/files/atoms/files/KCE_342_EQ-5D-5L_value_set_for_Belgium_Report_1.pdf}{PDF}}
    \item{\strong{Canada}: Xie F, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Med Care. 2016;54(1):98-105. \href{https://pubmed.ncbi.nlm.nih.gov/26492214/}{PubMed}}
    \item{\strong{China}: Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L Value Set for China. Value in Health. 2017 Apr;20(4):662-669. doi: 10.1016/j.jval.2016.11.016. Epub 2017 Feb 9. \href{https://pubmed.ncbi.nlm.nih.gov/28408009/}{PubMed}}
    \item{\strong{Denmark)}: Jensen CE, Sørensen SS, Gudex C, Jensen MB, Pedersen KM, Ehlers LH. The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data. Appl Health Econ Health Policy. 2021 Feb 2. doi: 10.1007/s40258-021-00639-3. Epub ahead of print. \href{https://pubmed.ncbi.nlm.nih.gov/33527304/}{PubMed}}
    \item{\strong{England}: Devlin N, Shah K, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of Life: An EQ-5D-5L Value Set for England. Health Economics. 2018 Jan;27(1):1-22 \href{https://pubmed.ncbi.nlm.nih.gov/28833869/}{PubMed}}
    \item{\strong{Ethiopia}: Welie AG, Gebretekle GB, Stolk E, Mukuria C, Krahn MD, Enquoselassie F, Fenta TG. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians. Value Health Reg Issues. 2019 Nov 1;22:7-14. doi: 10.1016/j.vhri.2019.08.475. \href{https://pubmed.ncbi.nlm.nih.gov/31683254/}{PubMed}}
    \item{\strong{France}: Andrade LF, Ludwig K, Goni JMR, Oppe M, de Pouvourville G. A French Value Set for the EQ-5D-5L. Pharmacoeconomics. 2020 Jan 8. doi: 10.1007/s40273-019-00876-4. \href{https://pubmed.ncbi.nlm.nih.gov/31912325/}{PubMed}}
    \item{\strong{Germany}: Ludwig K, Graf von der Schulenburg JM, Greiner W. German Value Set for the EQ-5D-5L. Pharmacoeconomics. 2018 Feb;36(6):663-674. doi: 10.1007/s40273-018-0615-8. \href{https://pubmed.ncbi.nlm.nih.gov/29460066/}{PubMed}}
    \item{\strong{HongKong}: Wong ELY, Ramos-Goñi JM, Cheung AWL, Wong AYK, Rivero-Arias O. Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong. Patient. 2018 Apr;11(2):235-247. doi: 10.1007/s40271-017-0278-0. \href{https://pubmed.ncbi.nlm.nih.gov/29019161/}{PubMed}}
    \item{\strong{Hungary}: Rencz F, Brodszky V, Gulácsi L, Golicki D, Ruzsa G, Pickard AS, Law EH, Péntek M. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Value Health. 2020 Sep;23(9):1235-1245. doi: 10.1016/j.jval.2020.03.019. Epub 2020 Aug 12. \href{https://pubmed.ncbi.nlm.nih.gov/32940242/}{PubMed}}
    \item{\strong{Indonesia}: Purba FD, Hunfeld JAM, Iskandarsyah A, Fitriana TS, Sadarjoen SS, Ramos-Goñi JM, Passchier J, Busschbach JJ. The Indonesian EQ-5D-5L Value Set. PharmacoEconomics. 2017 Nov;35(11)1153-1165. doi: 10.1007/s40273-017-0538-9. \href{https://pubmed.ncbi.nlm.nih.gov/28695543/}{PubMed}}
    \item{\strong{Ireland}: Hobbins A, Barry L, Kelleher D, Shah K, Devlin N, Ramos Goñi JM, O’Neill C. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L. PharmacoEconomics. 2018 Nov;36(11):1345-1353. doi: 10.1007/s40273-018-0690-x. \href{https://pubmed.ncbi.nlm.nih.gov/30051267/}{PubMed}}
    \item{\strong{Italy}: Finch AP, Meregaglia M, Ciani O, Roudijk B, Jommi C. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Social Science & Medicine. 2021 Oct. doi: 10.1016/j.socscimed.2021.114519. \href{https://www.sciencedirect.com/science/article/pii/S0277953621008510}{Journal}}
    \item{\strong{Japan}: Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, Shimozuma K. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. Value in Health. 2016 Jul-Aug;19(5):648-54. \href{https://pubmed.ncbi.nlm.nih.gov/27565282/}{PubMed}}
    \item{\strong{Malaysia}: Shafie AA; Vasan Thakumar A; Lim CJ;Luo N; Rand-Hendriksen K; Yusof FA. EQ-5D-5L Valuation for the Malaysian Population. PharmacoEconomics. 2019 May;37(5):715-725. doi: 10.1007/s40273-018-0758-7. \href{https://pubmed.ncbi.nlm.nih.gov/30535779/}{PubMed}}
    \item{\strong{Mexico}: Gutierrez-Delgado C, Galindo-Suárez RM, Cruz-Santiago C, Shah K, Papadimitropoulos M, Feng Y, Zamora B, Devlin N. EQ-5D-5L Health-State Values for the Mexican Population. Appl Health Econ Health Policy. 2021 Nov;19(6):905-914. doi: 10.1007/s40258-021-00658-0. Epub 2021 Jun 26. \href{https://pubmed.ncbi.nlm.nih.gov/34173957/}{PubMed}}
    \item{\strong{Netherlands} Versteegh MM, Vermeulen KM, Evers SM, de Wit GA, Prenger R, Stolk EA. Dutch Tariff for the Five-Level Version of EQ-5D. Value in Health. 2016 Jun;19(4):343-52.  doi: 10.1016/j.jval.2016.01.003. \href{https://pubmed.ncbi.nlm.nih.gov/27325326/}{PubMed}}
    \item{\strong{Peru} Augustovski F, Belizán M, Gibbons L, Reyes N, Stolk E, Craig BM, Tejada RA. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments. Value Health. 2020;23(7):880-888. doi:10.1016/j.jval.2020.05.004. \href{https://pubmed.ncbi.nlm.nih.gov/32762989/}{PubMed}}
    \item{\strong{Poland} Golicki D, Jakubczyk M, Niewada M, Wrona W, Busschbach JJ. Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe. Value Health. 2010 Mar-Apr;13(2):289-97. doi: 10.1111/j.1524-4733.2009.00596.x. \href{https://pubmed.ncbi.nlm.nih.gov/19744296/}{PubMed}}
    \item{\strong{Portugal} Ferreira PL, Antunes P, Ferreira LN, Pereira LN, Ramos-Goñi JM. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set. Qual Life Res. 2019 Jun 14. doi: 10.1007/s11136-019-02226-5. \href{https://pubmed.ncbi.nlm.nih.gov/31201730/}{PubMed}}
    \item{\strong{South Korea} Kim SH, Ahn J, Ock M, Shin S, Park J, Luo N, Jo MW. The EQ-5D-5L valuation study in Korea. Qual Life Res. 2016 Jul;25(7):1845-52. doi: 10.1007/s11136-015-1205-2. \href{https://pubmed.ncbi.nlm.nih.gov/26961008/}{PubMed}}
    \item{\strong{Spain}: Ramos-Goñi JM, Craig B, Oppe M, Ramallo-Fariña Y, Pinto-Prades JL, Luo N, Rivero-Arias O. Handling data quality issues to estimate the Spanish EQ-5D-5L Value Set using a hybrid interval regression approach.  Value in Health 2018 May;21(5):596-604. doi: 10.1016/j.jval.2017.10.023. \href{https://pubmed.ncbi.nlm.nih.gov/29753358/}{PubMed}}
    \item{\strong{Sweden}: Burström K, Teni FS, Gerdtham UG, Leidl R, Helgesson G, Rolfson O, Henriksson M. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States. Pharmacoeconomics. 2020 Apr 20. doi: 10.1007/s40273-020-00905-7. \href{https://pubmed.ncbi.nlm.nih.gov/32307663/}{PubMed}}
    \item{\strong{Taiwan}: Lin HW, Li CI, Lin FJ, Chang JY, Gau CS, Luo N, Pickard AS, Ramos Goñi JM, Tang CH, Hsu CN. Valuation of the EQ-5D-5L in Taiwan. PLoS One. 2018; 13(12):: e0209344. doi: 10.1371/journal.pone.0209344. \href{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306233/}{PubMed}}
    \item{\strong{Thailand} Pattanaphesaj J, Thavorncharoensap M, Ramos-Goñi JM, Tongsiri S, Ingsrisawang L, Teerawattananon Y. The EQ-5D-5L Valuation study in Thailand. Expert Review of Pharmacoeconomics & Outcomes Research. 2018 Oct;18(5):551-558. doi: 10.1080/14737167.2018.1494574 \href{https://pubmed.ncbi.nlm.nih.gov/29958008/}{PubMed}}
    \item{\strong{Uruguay}: Augustovski F, Rey-Ares L, Irazola V, Garay OU, Gianneo O, Fernández G, Morales M, Gibbons L, Ramos-Goñi JM. An EQ-5D-5L value set based on Uruguayan population preferences. Qual Life Res. 2016 Feb;25(2):323-33. doi: 10.1007/s11136-015-1086-4. \href{https://pubmed.ncbi.nlm.nih.gov/26242249/}{PubMed}}
    \item{\strong{USA}: Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman RH, Gong CL, Balch A, Busschbach JJV. United States Valuation of EQ-5D-5L Health States Using an International Protocol. Value in Health. 2019 Aug;22(8):931-941. doi: 10.1016/j.jval.2019.02.009. \href{https://pubmed.ncbi.nlm.nih.gov/31426935/}{PubMed}}
    \item{\strong{Vietnam}: Mai VQ, Sun S, Minh HV, Luo N, Giang KB, Lindholm L, Sahlen KG. An EQ-5D-5L Value Set for Vietnam. Qual Life Res. 2020;29(7):1923-1933. doi:10.1007/s11136-020-02469-7. \href{https://pubmed.ncbi.nlm.nih.gov/32221805/}{PubMed}}
  }
}
\usage{
VT
}
\description{
EQ-5D-5L VT value set calculation data for Canada, China, Denmark, Egypt, England, 
  France, Germany, Hong Kong, Hungary, Indonesia, Ireland, Japan, Malaysia, 
  Netherlands, Peru, Poland, Portugal, South Korea, Spain, Taiwan, Thailand, 
  Uruguay, Vietnam and USA.
}
\keyword{datasets}
